{
    "nctId": "NCT02364726",
    "briefTitle": "Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients",
    "officialTitle": "Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients: A Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Peripheral Neuropathy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "CIPN severity as measured by National Cancer Institute-Common Toxicity Criteria version 4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\nScreening Phase:\n\n* Age 21 or older.\n* Histologically proven stage I-III carcinoma of the breast.\n* Plan to receive adjuvant or neoadjuvant chemotherapy that includes weekly paclitaxel.\n* Eastern Cooperative Oncology Group performance status 0-2 (see Appendix B).\n* The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.\n* Proficiency in English with the ability to speak and read English.\n\nExclusion Criteria:\n\n* Known metastatic (stage IV) breast cancer involvement.\n* Pre-existing peripheral neuropathy within 28 days of screening consent\n* Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine.\n\nIntervention Phase:\n\n* Age 21 or older.\n* Histologically proven stage I-III carcinoma of the breast.\n* Receiving adjuvant or neoadjuvant chemotherapy that includes a taxane.\n* Eastern Cooperative Oncology Group performance status 0-2\n* The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.\n* Proficiency in English with the ability to speak and read English\n* While on neurotoxic chemotherapy, has developed NCI-CTC grade 2 CIPN\n\nExclusion Criteria:\n\n* Known metastatic (stage IV) breast cancer involvement.\n* Pre-existing peripheral neuropathy within 28 days of screening consent.\n* Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine.",
    "sex": "ALL",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}